Title:
FAP-α SPECIFIC RADIOPHARMACEUTICAL AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/143502
Kind Code:
A1
Abstract:
A precursor compound for forming a radionuclide complex, having the structure of formula I or formula II: wherein L is selected from -(CH2)m- and -CH2-PEG4-CH2-; L1 is -C(O)-L-NH-; BFC is a bifunctional chelating agent. A radiopharmaceutical is formed by the radionuclide-labeled precursor compound, and the pharmaceutical can be used as a diagnostic imaging agent or a radioactive targeted therapeutic agent for FAP-positive tumors or FAP-positive fibrotic diseases (such as pulmonary fibrosis and liver fibrosis).
Inventors:
SHI JIYUN (CN)
WANG FAN (CN)
YANG GUANGJIE (CN)
WANG FAN (CN)
YANG GUANGJIE (CN)
Application Number:
PCT/CN2023/073535
Publication Date:
August 03, 2023
Filing Date:
January 28, 2023
Export Citation:
Assignee:
INST BIOPHYSICS CAS (CN)
UNIV BEIJING (CN)
UNIV BEIJING (CN)
International Classes:
A61K31/4709; C07D401/12; A61P35/00; C07D401/14
Domestic Patent References:
| WO2021160825A1 | 2021-08-19 | |||
| WO2022171811A1 | 2022-08-18 | |||
| WO2021207682A2 | 2021-10-14 |
Foreign References:
| CN111991570A | 2020-11-27 | |||
| CN110101880A | 2019-08-09 | |||
| CN110227169A | 2019-09-13 | |||
| CN111228521A | 2020-06-05 | |||
| CN113616818A | 2021-11-09 |
Other References:
MILLUL, J. ET AL.: "An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 118, no. 16, 13 April 2021 (2021-04-13), XP055893845, DOI: 10.1073/pnas.2101852118
Attorney, Agent or Firm:
BEIJING ORIGINTELLIGENCE IP LAW FIRM (CN)
Download PDF: